Premium
Use of rituximab to treat a patient with coexistence of rheumatoid arthritis and ankylosing spondylitis: 18 months follow‐up
Author(s) -
Dundar U.,
Çevik H.,
Demirdal U. S.,
Toktas H.
Publication year - 2018
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.12303
Subject(s) - rituximab , medicine , ankylosing spondylitis , rheumatoid arthritis , tumor necrosis factor alpha , monoclonal , spondylitis , monoclonal antibody , immunology , antirheumatic agents , gastroenterology , antibody
Coexistence of rheumatoid arthritis ( RA ) and ankylosing spondylitis ( AS ) is rare. Tumor necrosis factor ( TNF ) inhibitor has been highly successful in controlling inflammation in many patients with AS or RA . Rituximab, which is a chimeric anti‐ CD 20 monoclonal antibody, has been proven effective in RA . Whether rituximab may be effective in AS is presently unclear. Here we report the 18 months follow‐up result of a coexisting AS and RA TNF inhibitor failed patient that was treated successfully with rituximab.